{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:18:44Z","timestamp":1792718324397,"version":"4.5.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T00:00:00Z","timestamp":1701216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Gilead Sciences, Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background and Aims<\/jats:title>\n                  <jats:p>SELECTION is the first study to assess the impact of concomitant thiopurine and other immunomodulator [IM] use on the efficacy and safety of a Janus kinase inhibitor, filgotinib, in patients with ulcerative colitis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Data from the phase 2b\/3 SELECTION study were used for this post hoc analysis. Patients were randomised [2:2:1] to two induction studies [biologic-naive, biologic-experienced] to filgotinib 200 mg, 100 mg, or placebo. At Week 10, patients receiving filgotinib were re-randomised [2:1] to continue filgotinib or to switch to placebo until Week 58 [maintenance]. Outcomes were compared between subgroups with and without concomitant IM use.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>At Week 10, similar proportions of patients in the +IM and \u2212IM groups treated with filgotinib 200 mg achieved Mayo Clinic Score [MCS] response [biologic-naive: 65.8% vs 66.9%; biologic-experienced: 61.3% vs 50.5%] and clinical remission [biologic-naive: 26.0% vs 26.2%; biologic-experienced: 11.3% vs 11.5%]. At Week 58, similar proportion of patients in the +IM and \u2212IM groups treated with filgotinib 200 mg achieved MCS response [biologic-naive: 74.2% vs 75.0%; biologic-experienced: 45.5% vs 61.4%] and clinical remission [biologic-naive: 51.6% vs 47.4%; biologic-experienced: 22.7% vs 24.3%]. The probability of protocol-specified disease worsening during the maintenance study in patients treated with filgotinib 200 mg did not differ between +IM and \u2212IM groups [p\u2005=\u20050.6700]. No differences were observed in the incidences of adverse events between +IM and \u2212IM groups in the induction\/maintenance studies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The efficacy and safety profiles of filgotinib treatment in SELECTION did not differ with or without concomitant IM use.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>ClinicalTrials.gov identifier<\/jats:title>\n                  <jats:p>NCT02914522.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjad201","type":"journal-article","created":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T18:59:31Z","timestamp":1701284371000},"page":"801-811","source":"Crossref","is-referenced-by-count":5,"title":["Impact of Concomitant Thiopurine on the Efficacy and Safety of Filgotinib in Patients with Ulcerative Colitis: Post Hoc Analysis of the Phase 2b\/3 SELECTION Study"],"prefix":"10.1093","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3781-4724","authenticated-orcid":false,"given":"Kenji","family":"Watanabe","sequence":"first","affiliation":[{"name":"Department of Internal Medicine for Inflammatory Bowel Disease, University of Toyama , Toyama , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, CHRU-Nancy, University of Lorraine , Nancy , France"},{"name":"Inserm, NGERE, University of Lorraine , Nancy , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7341-1351","authenticated-orcid":false,"given":"Silvio","family":"Danese","sequence":"additional","affiliation":[{"name":"Gastroenterology and Endoscopy, IRCCS Hospital San Raffaele , Milan , Italy"},{"name":"Vita-Salute San Raffaele University , Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Fujitani","sequence":"additional","affiliation":[{"name":"Gilead Sciences K.K. , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaux","family":"Faes","sequence":"additional","affiliation":[{"name":"Galapagos GmbH , Basel , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Oortwijn","sequence":"additional","affiliation":[{"name":"Galapagos NV , Oegstgeest , Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James O","family":"Lindsay","sequence":"additional","affiliation":[{"name":"Centre for Immunobiology, Blizard Institute, Barts and the London School of Medicine, Queen Mary University of London , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Rogler","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Hospital of Zurich, University of Zurich , Zurich , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Hibi","sequence":"additional","affiliation":[{"name":"Center for Advanced IBD Research and Treatment, Kitasato Institute Hospital, Kitasato University , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,11,29]]},"reference":[{"key":"2024060402062704600_CIT0001","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet"},{"key":"2024060402062704600_CIT0002","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.mayocp.2019.01.018","article-title":"Ulcerative colitis","volume":"94","author":"Feuerstein","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"2024060402062704600_CIT0003","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2147\/CEG.S57248","article-title":"Optimal management of steroid-dependent ulcerative colitis","volume":"8","author":"Khan","year":"2015","journal-title":"Clin Exp Gastroenterol"},{"key":"2024060402062704600_CIT0004","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s40268-019-0263-2","article-title":"Ulcerative colitis: shifting sands","volume":"19","author":"D\u2019Haens","year":"2019","journal-title":"Drugs R D"},{"key":"2024060402062704600_CIT0005","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41575-020-0273-0","article-title":"JAK\u2013STAT pathway targeting for the treatment of inflammatory bowel disease","volume":"17","author":"Salas","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2024060402062704600_CIT0006","author":"European Medicines Agency"},{"key":"2024060402062704600_CIT0007","author":"Galapagos"},{"key":"2024060402062704600_CIT0008","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/S0140-6736(21)00666-8","article-title":"Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b\/3 double-blind, randomised, placebo-controlled trial","volume":"397","author":"Feagan","year":"2021","journal-title":"Lancet"},{"key":"2024060402062704600_CIT0009","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/j.gastro.2013.10.052","article-title":"Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis","volume":"146","author":"Panaccione","year":"2014","journal-title":"Gastroenterology"},{"key":"2024060402062704600_CIT0010","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N Engl J Med"},{"key":"2024060402062704600_CIT0011","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/apt.13102","article-title":"Systematic review with meta-analysis: infliximab and immunosuppressant therapy vs. infliximab alone for active ulcerative colitis","volume":"41","author":"Christophorou","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"2024060402062704600_CIT0012","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.cgh.2018.09.033","article-title":"Combination therapy with infliximab and azathioprine improves infliximab pharmacokinetic features and efficacy: a post hoc analysis","volume":"17","author":"Colombel","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2024060402062704600_CIT0013","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1093\/ecco-jcc\/jjw152","article-title":"Adalimumab monotherapy and a combination with azathioprine for Crohn\u2019s disease: a prospective, randomised trial","volume":"10","author":"Matsumoto","year":"2016","journal-title":"J Crohns Colitis"},{"key":"2024060402062704600_CIT0014","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.cgh.2017.10.036","article-title":"Clinical and pharmacokinetic factors associated with adalimumab-induced mucosal healing in patients with Crohn\u2019s disease","volume":"16","author":"Watanabe","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2024060402062704600_CIT0015","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/jgh.15667","article-title":"Potential benefits of immunomodulator use with vedolizumab for maintenance of remission in ulcerative colitis","volume":"37","author":"Naganuma","year":"2022","journal-title":"J Gastroenterol Hepatol"},{"key":"2024060402062704600_CIT0016","author":"AbbVie"},{"key":"2024060402062704600_CIT0017","author":"Pfizer"},{"key":"2024060402062704600_CIT0018","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1136\/gut.47.3.404","article-title":"A reproducible grading scale for histological assessment of inflammation in ulcerative colitis","volume":"47","author":"Geboes","year":"2000","journal-title":"Gut"},{"key":"2024060402062704600_CIT0019","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2022"},{"key":"2024060402062704600_CIT0020","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1111\/apt.17674","article-title":"Integrated safety analysis of filgotinib for ulcerative colitis: results from SELECTION and SELECTIONLTE","volume":"58","author":"Schreiber","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"2024060402062704600_CIT0021","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/ecco-jcc\/jjac122","article-title":"Corticosteroid-sparing effects of filgotinib in moderate to severely active ulcerative colitis: data from the phase 2b\/3 SELECTION study","volume":"17","author":"Loftus","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2024060402062704600_CIT0022","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s00228-008-0478-6","article-title":"Clinical pharmacology and pharmacogenetics of thiopurines","volume":"64","author":"Sahasranaman","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"key":"2024060402062704600_CIT0023","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med"},{"key":"2024060402062704600_CIT0024","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials","volume":"399","author":"Danese","year":"2022","journal-title":"Lancet"},{"key":"2024060402062704600_CIT0025","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1053\/j.gastro.2020.02.030","article-title":"Efficacy of upadacitinib in a randomised trial of patients with active ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"2024060402062704600_CIT0026","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1136\/annrheumdis-2020-219213","article-title":"Filgotinib in combination with methotrexate or as monotherapy vs methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial","volume":"80","author":"Westhovens","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2024060402062704600_CIT0027","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","article-title":"Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial","volume":"390","author":"Fleischmann","year":"2017","journal-title":"Lancet"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjad201\/54770455\/jjad201.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/18\/6\/801\/58069574\/jjad201.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/18\/6\/801\/58069574\/jjad201.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T02:07:18Z","timestamp":1717466838000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/18\/6\/801\/7455251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,29]]},"references-count":27,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,11,29]]},"published-print":{"date-parts":[[2024,6,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjad201","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,6,1]]},"published":{"date-parts":[[2023,11,29]]}}}